A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
ID Number 11-0694
Principal Investigator(s)Randall Holcombe
Department(s) or Division(s)
Hematology and Medical Oncology
Description
The purpose of this study is to see how safe the investigational drug ramucirumab is and how well it will work to help people with colorectal cancer (also known as colon cancer). Colorectal cancer is a malignant (cancerous) growth that develops inside the large bowel. “Investigational” means that the drug being tested, ramucirumab has not been approved for routine clinical use or for the use described in this study by the United States Food and Drug Administration (FDA). However the FDA has allowed the use of this drug for research.
The primary purpose of your participation in this study is to help answer the following research questions:
• Can ramuicrumab help patients with your condition live longer?
• What can we learn about the safety of ramucirumab?
You may qualify to take part in this research study because you have metastatic colorectal cancer with disease progression during or following first-line combination therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.
Contact Information
(212) 824-7117
(212) 824-7293
Recruiting Patients: Yes